ORGO

SEC source: 0001661181-21-000025 · edgar.xml · nonDerivative · entry 2

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,644

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.76 to $13.75, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

SEC source: 0001661181-21-000013 · edgar.xml · nonDerivative · entry 4

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,219

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020.

F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.71 to $13.67, inclusive. The reporting person undertakes to provide to ORGO, any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.

SEC source: 0001661181-21-000033 · edgar.xml · derivative · entry 2

Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,246

Underlying: Class A Common Stock · 63,246 shares

Expires 2031-02-16

F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 16, 2021.

SEC source: 0001661181-21-000033 · edgar.xml · nonDerivative · entry 1

Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,326

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 16, 2021.

SEC source: 0001661181-21-000021 · edgar.xml · nonDerivative · entry 2

Tamaroff Joshua Alexander · CIK 0001705548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,364

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock.

F3 · kind: The RSUs vest in full on February 16, 2022.

SEC source: 0001661181-21-000021 · edgar.xml · nonDerivative · entry 1

Tamaroff Joshua Alexander · CIK 0001705548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,882

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock.

F2 · kind: The RSUs vest in full on April 1, 2022.

SEC source: 0001661181-21-000019 · edgar.xml · nonDerivative · entry 2

Leibowitz Arthur S · CIK 0001467329 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,307

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock.

F3 · kind: The RSUs vest in full on February 16, 2022.

SEC source: 0001661181-21-000019 · edgar.xml · nonDerivative · entry 1

Leibowitz Arthur S · CIK 0001467329 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,825

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock.

F2 · kind: The RSUs vest in full on April 1, 2022.

SEC source: 0001661181-21-000029 · edgar.xml · derivative · entry 2

Freedman Lori · CIK 0001410291 · VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,444

Underlying: Class A Common Stock · 67,444 shares

Expires 2031-02-16

F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 16, 2021.

SEC source: 0001661181-21-000029 · edgar.xml · nonDerivative · entry 1

Freedman Lori · CIK 0001410291 · VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,726

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 16, 2021.

SEC source: 0001661181-21-000023 · edgar.xml · nonDerivative · entry 2

MACKIE WAYNE D · CIK 0001240034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 211,800

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock.

F3 · kind: The RSUs vest in full on February 16, 2022.

SEC source: 0001661181-21-000023 · edgar.xml · nonDerivative · entry 1

MACKIE WAYNE D · CIK 0001240034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,318

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock.

F2 · kind: The RSUs vest in full on April 1, 2022.

SEC source: 0001661181-21-000035 · edgar.xml · derivative · entry 2

Francisco David · CIK 0001846282 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,955

Underlying: Class A Common Stock · 83,955 shares

Expires 2031-02-16

F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 16, 2021.

SEC source: 0001661181-21-000035 · edgar.xml · nonDerivative · entry 1

Francisco David · CIK 0001846282 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,361

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 16, 2021.

SEC source: 0001661181-21-000031 · edgar.xml · derivative · entry 2

Grow Brian · CIK 0001759142 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,556

Underlying: Class A Common Stock · 82,556 shares

Expires 2031-02-16

F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 16, 2021.

SEC source: 0001661181-21-000031 · edgar.xml · nonDerivative · entry 1

Grow Brian · CIK 0001759142 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,549

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 16, 2021.

SEC source: 0001661181-21-000027 · edgar.xml · derivative · entry 2

Bilbo Patrick · CIK 0001759203 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,556

Underlying: Class A Common Stock · 82,556 shares

Expires 2031-02-16

F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 16, 2021.

SEC source: 0001661181-21-000027 · edgar.xml · nonDerivative · entry 1

Bilbo Patrick · CIK 0001759203 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,617

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 16, 2021.

SEC source: 0001661181-21-000025 · edgar.xml · derivative · entry 5

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 395,289

Underlying: Class A Common Stock · 395,289 shares

Expires 2031-02-16

F6 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 16, 2021.

SEC source: 0001661181-21-000025 · edgar.xml · nonDerivative · entry 1

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,845

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 16, 2021.

SEC source: 0001661181-21-000046 · edgar.xml · nonDerivative · entry 6

Wisdom Starr · CIK 0001760694 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,539

SEC source: 0001661181-21-000017 · edgar.xml · derivative · entry 2

Francisco David · CIK 0001846282 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,239

Underlying: Class A Common Stock · 43,239 shares

Expires 2031-02-15

F2 · derivative.exercise_date: The option becomes fully exercisable on February 15, 2022.

SEC source: 0001661181-21-000017 · edgar.xml · nonDerivative · entry 1

Francisco David · CIK 0001846282 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,396

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2022.

SEC source: 0001661181-21-000013 · edgar.xml · nonDerivative · entry 3

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,625

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.58 to $14.02, inclusive. The reporting person undertakes to provide to ORGO, any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

SEC source: 0001661181-21-000013 · edgar.xml · nonDerivative · entry 2

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 339,016

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.565 to $13.53, inclusive. The reporting person undertakes to provide to ORGO, any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

SEC source: 0001661181-21-000046 · edgar.xml · nonDerivative · entry 5

Wisdom Starr · CIK 0001760694 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,539

SEC source: 0001661181-21-000046 · edgar.xml · nonDerivative · entry 4

Wisdom Starr · CIK 0001760694 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,939

SEC source: 0001661181-21-000046 · edgar.xml · nonDerivative · entry 3

Wisdom Starr · CIK 0001760694 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 276,939

SEC source: 0001661181-21-000010 · edgar.xml · nonDerivative · entry 1

Ades Alan A. · CIK 0001757286 · Director · 10% owner

ERANI ALBERT · CIK 0001074084 · 10% owner

Erani Dennis · CIK 0001760685 · 10% owner

Organo PFG LLC · CIK 0001757580 · 10% owner

Organo Investors LLC · CIK 0001757573 · 10% owner

Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner

Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner

Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner

GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner

GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,594,976

F1 · shares: The reported securities sold were held directly by Alan A. Ades, who is a member of the Group (as defined below). On November 17, 2020, Mr. Ades purchased shares of Class A common stock of Organogenesis Holdings Inc. at a price of $3.25 per share, including (i) 100,000 shares purchased by Mr. Ades as agent for and for the benefit of one of his sons and (ii) 100,000 shares purchased by Mr. Ades as agent for and for the benefit of an entity that is managed by Mr. Ades' son-in-law. This Form 4 reflects the sales of such shares.

SEC source: 0001661181-21-000011 · edgar.xml · nonDerivative · entry 1

NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner

Wisdom Starr · CIK 0001760694 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,594,976

F1 · shares: The reported securities sold were held directly by Alan A. Ades, who is a member of the Group (as defined below). On November 17, 2020, Mr. Ades purchased shares of Class A common stock of Organogenesis Holdings Inc. at a price of $3.25 per share, including (i) 100,000 shares purchased by Mr. Ades as agent for and for the benefit of one of his sons and (ii) 100,000 shares purchased by Mr. Ades as agent for and for the benefit of an entity that is managed by Mr. Ades' son-in-law. This Form 4 reflects the sales of such shares.

SEC source: 0001661181-21-000013 · edgar.xml · nonDerivative · entry 1

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 416,954

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $14.22, inclusive. The reporting person undertakes to provide to Organogenesis Holdings Inc. ("ORGO"), any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001661181-21-000046 · edgar.xml · nonDerivative · entry 2

Wisdom Starr · CIK 0001760694 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 362,457

SEC source: 0001661181-21-000003 · edgar.xml · derivative · entry 2

Hagopian Henry III · CIK 0001821822 · Interim CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,198

Underlying: Class A Common Stock · 64,198 shares

Expires 2031-01-13

F2 · derivative.exercise_date: The option becomes exercisable in equal yearly installments over four years from the date of grant.

SEC source: 0001661181-21-000003 · edgar.xml · nonDerivative · entry 1

Hagopian Henry III · CIK 0001821822 · Interim CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,073

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years from the date of grant.

SEC source: 0001661181-21-000006 · edgar.xml · nonDerivative · entry 2

Ades Alan A. · CIK 0001757286 · Director · 10% owner

ERANI ALBERT · CIK 0001074084 · 10% owner

Erani Dennis · CIK 0001760685 · 10% owner

Organo PFG LLC · CIK 0001757580 · 10% owner

Organo Investors LLC · CIK 0001757573 · 10% owner

Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner

Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner

Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner

GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner

GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,794,976

F1 · shares: Such shares were previously held by GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 (the "GN 2016 GRAT"), a member of the Group (as defined below). On December 29, 2020, the GN 2016 GRAT distributed 251,430 shares of Class A Common Stock of Organogenesis Holdings Inc. to Glenn H. Nussdorf in satisfaction of its annuity obligation and in an exempt transaction pursuant to Rule 16a-13. On December 29, 2020, Glenn H. Nussdorf transferred 251,430 shares of Class A Common Stock of Organogenesis Holdings Inc. to GN 2016 Family Trust u/a/d August 12, 2016 for no consideration. Each of Glenn H. Nussdorf and GN 2016 Family Trust u/a/d August 12, 2016 is a member of the Group.

SEC source: 0001661181-21-000006 · edgar.xml · nonDerivative · entry 1

Ades Alan A. · CIK 0001757286 · Director · 10% owner

ERANI ALBERT · CIK 0001074084 · 10% owner

Erani Dennis · CIK 0001760685 · 10% owner

Organo PFG LLC · CIK 0001757580 · 10% owner

Organo Investors LLC · CIK 0001757573 · 10% owner

Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner

Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner

Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner

GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner

GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,543,546

F1 · shares: Such shares were previously held by GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 (the "GN 2016 GRAT"), a member of the Group (as defined below). On December 29, 2020, the GN 2016 GRAT distributed 251,430 shares of Class A Common Stock of Organogenesis Holdings Inc. to Glenn H. Nussdorf in satisfaction of its annuity obligation and in an exempt transaction pursuant to Rule 16a-13. On December 29, 2020, Glenn H. Nussdorf transferred 251,430 shares of Class A Common Stock of Organogenesis Holdings Inc. to GN 2016 Family Trust u/a/d August 12, 2016 for no consideration. Each of Glenn H. Nussdorf and GN 2016 Family Trust u/a/d August 12, 2016 is a member of the Group.

SEC source: 0001661181-21-000007 · edgar.xml · nonDerivative · entry 2

NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner

Wisdom Starr · CIK 0001760694 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,794,976

F1 · shares: Such shares were previously held by GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 (the "GN 2016 GRAT"), a member of the Group (as defined below). On December 29, 2020, the GN 2016 GRAT distributed 251,430 shares of Class A Common Stock of Organogenesis Holdings Inc. to Glenn H. Nussdorf in satisfaction of its annuity obligation and in an exempt transaction pursuant to Rule 16a-13. On December 29, 2020, Glenn H. Nussdorf transferred 251,430 shares of Class A Common Stock of Organogenesis Holdings Inc. to GN 2016 Family Trust u/a/d August 12, 2016 for no consideration. Each of Glenn H. Nussdorf and GN 2016 Family Trust u/a/d August 12, 2016 is a member of the Group.

SEC source: 0001661181-21-000007 · edgar.xml · nonDerivative · entry 1

NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner

Wisdom Starr · CIK 0001760694 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,543,546

F1 · shares: Such shares were previously held by GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 (the "GN 2016 GRAT"), a member of the Group (as defined below). On December 29, 2020, the GN 2016 GRAT distributed 251,430 shares of Class A Common Stock of Organogenesis Holdings Inc. to Glenn H. Nussdorf in satisfaction of its annuity obligation and in an exempt transaction pursuant to Rule 16a-13. On December 29, 2020, Glenn H. Nussdorf transferred 251,430 shares of Class A Common Stock of Organogenesis Holdings Inc. to GN 2016 Family Trust u/a/d August 12, 2016 for no consideration. Each of Glenn H. Nussdorf and GN 2016 Family Trust u/a/d August 12, 2016 is a member of the Group.

SEC source: 0001661181-20-000045 · edgar.xml · nonDerivative · entry 1

MACKIE WAYNE D · CIK 0001240034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.27, inclusive. The reporting person undertakes to provide to Organogenesis Holdings Inc. ("ORGO"), any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

SEC source: 0001140361-20-026482 · form4.xml · nonDerivative · entry 2

Avista Capital Managing Member IV, LLC · CIK 0001761175 · Director · 10% owner

Avista Acquisition Corp. · CIK 0001661187 · Director · 10% owner

Avista Acquisition, LLC · CIK 0001686388 · Director · 10% owner

Avista Capital Partners IV, L.P. · CIK 0001664176 · Director · 10% owner

Avista Capital Partners (Offshore) IV, L.P. · CIK 0001664173 · Director · 10% owner

Avista Capital Partners IV GP, L.P. · CIK 0001761195 · Director · 10% owner

Dean Thompson · CIK 0001069096 · Director · 10% owner

Burgstahler David F · CIK 0001374179 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Notes

Disclosed balance after: 29,924,515

F5 · shares: Represents an aggregate of 50 shares of Common Stock purchased by ACP Onshore and 50 shares of Common Stock purchased by ACP Offshore.

F1 · ownership.nature: This statement is being filed by the following Reporting Persons: Avista Acquisition Corp. (the "Sponsor"); Avista Acquisition LLC, which is the sole shareholder of the Sponsor; Avista Capital Partners IV, L.P. ("ACP Onshore"); Avista Capital Partners (Offshore) IV, L.P. ("ACP Offshore"); Avista Capital Partners IV GP, L.P. ("Avista GP"), which is the general partner of ACP Onshore and ACP Offshore; Avista Capital Managing Member IV, LLC, which is the general partner of Avista GP; Thompson Dean; and David Burgstahler.

F6 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. Joshua Tamaroff, an employee of an affiliate of the Reporting Persons, serves on the board of directors of the Issuer as a representative of the Reporting Persons.

F7 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests

SEC source: 0001140361-20-026482 · form4.xml · nonDerivative · entry 1

Avista Capital Managing Member IV, LLC · CIK 0001761175 · Director · 10% owner

Avista Acquisition Corp. · CIK 0001661187 · Director · 10% owner

Avista Acquisition, LLC · CIK 0001686388 · Director · 10% owner

Avista Capital Partners IV, L.P. · CIK 0001664176 · Director · 10% owner

Avista Capital Partners (Offshore) IV, L.P. · CIK 0001664173 · Director · 10% owner

Avista Capital Partners IV GP, L.P. · CIK 0001761195 · Director · 10% owner

Dean Thompson · CIK 0001069096 · Director · 10% owner

Burgstahler David F · CIK 0001374179 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Notes

Disclosed balance after: 29,924,415

F2 · shares: The number of securities reported represents an aggregate number of shares of Class A common stock of the Issuer ("Common Stock") purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. Each Reporting Person undertakes to provide the staff of the Securities and Exchange Commission, the Issuer, or a stockholder of the Issuer, upon request, the number of shares of Common Stock purchased by the Reporting Person at each separate price within the range.

F3 · shares: Represents an aggregate of 1,373 shares of Common Stock purchased by ACP Onshore and 1,366 shares of Common Stock purchased by ACP Offshore.

F4 · price: Purchase prices range from $4.98 to $5.00 per share, inclusive.

F1 · ownership.nature: This statement is being filed by the following Reporting Persons: Avista Acquisition Corp. (the "Sponsor"); Avista Acquisition LLC, which is the sole shareholder of the Sponsor; Avista Capital Partners IV, L.P. ("ACP Onshore"); Avista Capital Partners (Offshore) IV, L.P. ("ACP Offshore"); Avista Capital Partners IV GP, L.P. ("Avista GP"), which is the general partner of ACP Onshore and ACP Offshore; Avista Capital Managing Member IV, LLC, which is the general partner of Avista GP; Thompson Dean; and David Burgstahler.

F6 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. Joshua Tamaroff, an employee of an affiliate of the Reporting Persons, serves on the board of directors of the Issuer as a representative of the Reporting Persons.

F7 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests

SEC source: 0001140361-20-026147 · form4.xml · nonDerivative · entry 4

Avista Capital Managing Member IV, LLC · CIK 0001761175 · Director · 10% owner

Avista Acquisition Corp. · CIK 0001661187 · Director · 10% owner

Avista Acquisition, LLC · CIK 0001686388 · Director · 10% owner

Avista Capital Partners IV, L.P. · CIK 0001664176 · Director · 10% owner

Avista Capital Partners (Offshore) IV, L.P. · CIK 0001664173 · Director · 10% owner

Avista Capital Partners IV GP, L.P. · CIK 0001761195 · Director · 10% owner

Dean Thompson · CIK 0001069096 · Director · 10% owner

Burgstahler David F · CIK 0001374179 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Notes

Disclosed balance after: 29,921,676

F4 · shares: The number of securities reported represents an aggregate number of shares of Common Stock purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. Each Reporting Person undertakes to provide the staff of the Securities and Exchange Commission, the Issuer, or a stockholder of the Issuer, upon request, the number of shares of Common Stock purchased by the Reporting Person at each separate price within the range.

F9 · shares: Represents an aggregate of 18,111 shares of Common Stock purchased by ACP Onshore and 18,016 shares of Common Stock purchased by ACP Offshore.

F10 · price: Purchase prices range from $4.86 to $5.00 per share, inclusive.

F1 · ownership.nature: This statement is being filed by the following Reporting Persons: Avista Acquisition Corp. (the "Sponsor"); Avista Acquisition LLC, which is the sole shareholder of the Sponsor; Avista Capital Partners IV, L.P. ("ACP Onshore"); Avista Capital Partners (Offshore) IV, L.P. ("ACP Offshore"); Avista Capital Partners IV GP, L.P. ("Avista GP"), which is the general partner of ACP Onshore and ACP Offshore; Avista Capital Managing Member IV, LLC, which is the general partner of Avista GP; Thompson Dean; and David Burgstahler.

F11 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. Joshua Tamaroff, an employee of an affiliate of the Reporting Persons, serves on the board of directors of the Issuer as a representative of the Reporting Persons.

F12 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0001140361-20-026147 · form4.xml · nonDerivative · entry 3

Avista Capital Managing Member IV, LLC · CIK 0001761175 · Director · 10% owner

Avista Acquisition Corp. · CIK 0001661187 · Director · 10% owner

Avista Acquisition, LLC · CIK 0001686388 · Director · 10% owner

Avista Capital Partners IV, L.P. · CIK 0001664176 · Director · 10% owner

Avista Capital Partners (Offshore) IV, L.P. · CIK 0001664173 · Director · 10% owner

Avista Capital Partners IV GP, L.P. · CIK 0001761195 · Director · 10% owner

Dean Thompson · CIK 0001069096 · Director · 10% owner

Burgstahler David F · CIK 0001374179 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Notes

Disclosed balance after: 29,885,549

F4 · shares: The number of securities reported represents an aggregate number of shares of Common Stock purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. Each Reporting Person undertakes to provide the staff of the Securities and Exchange Commission, the Issuer, or a stockholder of the Issuer, upon request, the number of shares of Common Stock purchased by the Reporting Person at each separate price within the range.

F7 · shares: Represents an aggregate of 22,747 shares of Common Stock purchased by ACP Onshore and 22,631 shares of Common Stock purchased by ACP Offshore.

F8 · price: Purchase prices range from $4.58 to $4.75 per share, inclusive.

F1 · ownership.nature: This statement is being filed by the following Reporting Persons: Avista Acquisition Corp. (the "Sponsor"); Avista Acquisition LLC, which is the sole shareholder of the Sponsor; Avista Capital Partners IV, L.P. ("ACP Onshore"); Avista Capital Partners (Offshore) IV, L.P. ("ACP Offshore"); Avista Capital Partners IV GP, L.P. ("Avista GP"), which is the general partner of ACP Onshore and ACP Offshore; Avista Capital Managing Member IV, LLC, which is the general partner of Avista GP; Thompson Dean; and David Burgstahler.

F11 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. Joshua Tamaroff, an employee of an affiliate of the Reporting Persons, serves on the board of directors of the Issuer as a representative of the Reporting Persons.

F12 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0001661181-20-000036 · edgar.xml · nonDerivative · entry 2

Ades Alan A. · CIK 0001757286 · Director · 10% owner

ERANI ALBERT · CIK 0001074084 · 10% owner

Erani Dennis · CIK 0001760685 · 10% owner

Organo PFG LLC · CIK 0001757580 · 10% owner

Organo Investors LLC · CIK 0001757573 · 10% owner

Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner

Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner

Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner

GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner

GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Robert Harry Erani Frick Trust

Disclosed balance after: 68,794,976

F2 · shares: The reported securities were purchased by the Robert Harry Erani Frick Trust (the "Trust") and are held indirectly by Dennis Erani, who is a member of the Group. Susan Erani, Dennis Erani's spouse, and Glenn Nussdorf are co-trustees of the Trust. Dennis Erani disclaims beneficial ownership of the securities held by the Trust, except to the extent of his pecuniary interest therein.

SEC source: 0001661181-20-000036 · edgar.xml · nonDerivative · entry 1

Ades Alan A. · CIK 0001757286 · Director · 10% owner

ERANI ALBERT · CIK 0001074084 · 10% owner

Erani Dennis · CIK 0001760685 · 10% owner

Organo PFG LLC · CIK 0001757580 · 10% owner

Organo Investors LLC · CIK 0001757573 · 10% owner

Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner

Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner

Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner

GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner

GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,447,823

F1 · shares: The reported securities were purchased and are held directly by Alan A. Ades, who is a member of the Group.

SEC source: 0001140361-20-026147 · form4.xml · nonDerivative · entry 2

Avista Capital Managing Member IV, LLC · CIK 0001761175 · Director · 10% owner

Avista Acquisition Corp. · CIK 0001661187 · Director · 10% owner

Avista Acquisition, LLC · CIK 0001686388 · Director · 10% owner

Avista Capital Partners IV, L.P. · CIK 0001664176 · Director · 10% owner

Avista Capital Partners (Offshore) IV, L.P. · CIK 0001664173 · Director · 10% owner

Avista Capital Partners IV GP, L.P. · CIK 0001761195 · Director · 10% owner

Dean Thompson · CIK 0001069096 · Director · 10% owner

Burgstahler David F · CIK 0001374179 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Notes

Disclosed balance after: 29,840,171

F4 · shares: The number of securities reported represents an aggregate number of shares of Common Stock purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. Each Reporting Person undertakes to provide the staff of the Securities and Exchange Commission, the Issuer, or a stockholder of the Issuer, upon request, the number of shares of Common Stock purchased by the Reporting Person at each separate price within the range.

F5 · shares: Represents an aggregate of 25,065 shares of Common Stock purchased by ACP Onshore and 24,935 shares of Common Stock purchased by ACP Offshore.

F6 · price: Purchase prices range from $4.38 to $4.50 per share, inclusive.

F1 · ownership.nature: This statement is being filed by the following Reporting Persons: Avista Acquisition Corp. (the "Sponsor"); Avista Acquisition LLC, which is the sole shareholder of the Sponsor; Avista Capital Partners IV, L.P. ("ACP Onshore"); Avista Capital Partners (Offshore) IV, L.P. ("ACP Offshore"); Avista Capital Partners IV GP, L.P. ("Avista GP"), which is the general partner of ACP Onshore and ACP Offshore; Avista Capital Managing Member IV, LLC, which is the general partner of Avista GP; Thompson Dean; and David Burgstahler.

F11 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. Joshua Tamaroff, an employee of an affiliate of the Reporting Persons, serves on the board of directors of the Issuer as a representative of the Reporting Persons.

F12 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0001140361-20-026147 · form4.xml · nonDerivative · entry 1

Avista Capital Managing Member IV, LLC · CIK 0001761175 · Director · 10% owner

Avista Acquisition Corp. · CIK 0001661187 · Director · 10% owner

Avista Acquisition, LLC · CIK 0001686388 · Director · 10% owner

Avista Capital Partners IV, L.P. · CIK 0001664176 · Director · 10% owner

Avista Capital Partners (Offshore) IV, L.P. · CIK 0001664173 · Director · 10% owner

Avista Capital Partners IV GP, L.P. · CIK 0001761195 · Director · 10% owner

Dean Thompson · CIK 0001069096 · Director · 10% owner

Burgstahler David F · CIK 0001374179 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Notes

Disclosed balance after: 29,790,171

F2 · shares: Represents an aggregate of 2,142,071 shares of Class A common stock of the Issuer ("Common Stock") purchased by ACP Onshore and 2,130,586 shares of Common Stock purchased by ACP Offshore in the Issuer's underwritten public offering (the "Offering") that was completed on November 17, 2020.

F3 · price: Represents the public offering price of $3.25 per share of Common Stock, without giving effect to the fee paid by the Issuer to Avista Capital Holdings, L.P., an affiliate of the Avista Funds ("Avista Management"), pursuant to the Fee Letter Agreement, dated November 12, 2020, among the Issuer, Avista Management and the Avista Funds, made in connection with the Offering, as described in the Issuer's Current Report on Form 8-K filed on November 18, 2020 and filed as Exhibit 10.1 thereto.

F1 · ownership.nature: This statement is being filed by the following Reporting Persons: Avista Acquisition Corp. (the "Sponsor"); Avista Acquisition LLC, which is the sole shareholder of the Sponsor; Avista Capital Partners IV, L.P. ("ACP Onshore"); Avista Capital Partners (Offshore) IV, L.P. ("ACP Offshore"); Avista Capital Partners IV GP, L.P. ("Avista GP"), which is the general partner of ACP Onshore and ACP Offshore; Avista Capital Managing Member IV, LLC, which is the general partner of Avista GP; Thompson Dean; and David Burgstahler.

F11 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. Joshua Tamaroff, an employee of an affiliate of the Reporting Persons, serves on the board of directors of the Issuer as a representative of the Reporting Persons.

F12 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0001661181-20-000039 · edgar.xml · nonDerivative · entry 1

Leibowitz Arthur S · CIK 0001467329 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,507

SEC source: 0001661181-20-000043 · edgar.xml · nonDerivative · entry 1

KATZ MICHAEL W · CIK 0001279930 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,432

SEC source: 0001661181-20-000037 · edgar.xml · nonDerivative · entry 2

NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner

Wisdom Starr · CIK 0001760694 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Robert Harry Erani Frick Trust

Disclosed balance after: 68,794,976

F2 · shares: The reported securities were purchased by the Robert Harry Erani Frick Trust (the "Trust") and are held indirectly by Dennis Erani, who is a member of the Group. Susan Erani, Dennis Erani's spouse, and Glenn Nussdorf are co-trustees of the Trust. Dennis Erani disclaims beneficial ownership of the securities held by the Trust, except to the extent of his pecuniary interest therein.